Cytek Biosciences (CTKB) Receivables Refunds (2020 - 2021)
Cytek Biosciences posted quarterly Receivables Refunds of $1.4 million for Q3 2021, down 5.11% on a QoQ basis from $1.4 million in Q2 2021.
Cytek Biosciences (CTKB) has 2 years of Receivables Refunds data on file, last reported at $1.4 million in Q3 2021.
- For the quarter ending Q3 2021, Receivables Refunds changed N/A year-over-year to $1.4 million; the trailing twelve-month figure through Sep 2021 stood at $1.4 million (changed N/A YoY), and the FY2020 full-year result was $1.1 million, changed N/A from the prior year.
- Receivables Refunds for Q3 2021 stood at $1.4 million, down from $1.4 million in the prior quarter.
- Across five years, Receivables Refunds topped out at $1.4 million in Q2 2021 and bottomed at $1.1 million in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Refund Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 52.68 Mn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Cytek Biosciences | - | - | 21.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 1.37 Mn |
| Jun 30, 2021 | 1.45 Mn |
| Dec 31, 2020 | 1.11 Mn |